Does Selpercatinib 80 Mg Capsule Interact with other Medications?
Severe Interactions
These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- P-GLYCOPROTEIN (P-GP) INHIB/COLCHICINE (CARDIOPROTECTION)
- WEAK CYP3A4 INHIBITORS/LEMBOREXANT (> 5 MG)
- WEAK CYP3A4 INHIBITORS/LOMITAPIDE (>30 MG)
Serious Interactions
These medications may interact and cause very harmful effects. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- SELPERCATINIB/QT PROLONGING AGENTS
- SELPERCATINIB/STRONG CYP3A4 INHIBITORS
- SELPERCATINIB/STRONG CYP3A4 INHIBITORS THAT PROLONG QT
- SELPERCATINIB/MODERATE CYP3A4 INHIBITORS THAT PROLONG QT
- SELPERCATINIB/MODERATE CYP3A4 INHIBITORS
- SELPERCATINIB/STRONG AND MODERATE CYP3A4 INDUCERS
- SELPERCATINIB/PROTON PUMP INHIBITORS
- INFIGRATINIB; SELPERCATINIB/SELECTED H2 ANTAGONISTS
- SELPERCATINIB/LONAFARNIB
- SELPERCATINIB/STRONG AND MOD CYP3A4 INDUCERS THAT PROLONG QT
- SELPERCATINIB/VONOPRAZAN-CLARITHROMYCIN
- MODERATE CYP2C8 INHIBITORS/TOVORAFENIB
- P-GLYCOPROTEIN (P-GP) INHIBITORS/VINCRISTINE
- SELPERCATINIB/SELECTED P-GLYCOPROTEIN (P-GP) SUBSTRATES
- P-GLYCOPROTEIN (P-GP) INHIBITORS/DOXORUBICIN
- MYELOSUPPRESSIVES; IMMUNOMODULATORS/SODIUM IODIDE I 131
- P-GLYCOPROTEIN (P-GP) INHIBITORS/RELUGOLIX
- P-GP OR BCRP INHIBITORS THAT PROLONG QT/PAZOPANIB
- WEAK CYP3A4 INHIBITORS/ELIGLUSTAT
- SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/VENETOCLAX
- P-GLYCOPROTEIN (P-GP) INHIBITORS/COLCHICINE
- WEAK CYP3A4 INHIBITORS/LOMITAPIDE (<=30MG)
- P-GLYCOPROTEIN (P-GP) INHIBITORS/TOPOTECAN
- SELECTED QT PROLONGING AGENTS/ZIPRASIDONE
- POSSIBLE QT PROLONGING AGENTS/SERTINDOLE
Moderate Interactions
These medications may cause some risk when taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.
- SELPERCATINIB/POSSIBLE QT PROLONGING AGENTS
- INFIGRATINIB; SELPERCATINIB/ANTACIDS
- MODERATE CYP2C8 INHIBITORS/RESMETIROM
- POSSIBLE QT PROLONGING AGENTS/DEXMEDETOMIDINE SUBLINGUAL
- CYP2C8 INHIBITORS THAT PROLONG QT/ETRASIMOD
- QT PROLONGING AGENTS/GEPIRONE
- MODERATE CYP2C8 INHIBITORS/DAPRODUSTAT
- QT PROLONGING AGENTS/TUCIDINOSTAT
- QT PROLONGING AGENTS/TRICLABENDAZOLE
- POSSIBLE QT PROLONGING AGENTS/PACRITINIB
- SELECTED POSSIBLE QT PROLONGING AGENTS/INTRAVENOUS LEFAMULIN
- QT PROLONGING AGENTS/OZANIMOD
- QT PROLONGING AGENTS/PONESIMOD
- QT PROLONGING AGENTS/SIPONIMOD
- POSSIBLE QT PROLONGING AGENTS/FEXINIDAZOLE
- QT PROLONGING AGENTS/GALANTAMINE
- POSSIBLE QT PROLONGING AGENTS/LEVOMEPROMAZINE
- WEAK CYP3A4 INHIBITORS/LEMBOREXANT (<= 5 MG)
- MODERATE & WEAK CYP3A4 INHIBITORS THAT PROLONG QT/TACROLIMUS
- MODERATE CYP2C8 INHIBITORS/SELEXIPAG
- SELECTED STRONG AND MODERATE CYP2C8 INHIBITORS/PACLITAXEL
- QT PROLONGING AGENTS/FINGOLIMOD
- POSSIBLE QT PROLONGING AGENTS/GADOFOSVESET
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.